Rockefeller Capital Management L.P. Acquires New Stake in Thermo Fisher Scientific (TMO)

Rockefeller Capital Management L.P. acquired a new position in Thermo Fisher Scientific (NYSE:TMO) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 19,395 shares of the medical research company’s stock, valued at approximately $4,004,000.

Several other institutional investors have also recently modified their holdings of TMO. Viking Global Investors LP acquired a new position in shares of Thermo Fisher Scientific in the fourth quarter worth about $154,660,000. Cornerstone Investment Partners LLC raised its position in shares of Thermo Fisher Scientific by 89.8% in the fourth quarter. Cornerstone Investment Partners LLC now owns 802,374 shares of the medical research company’s stock worth $152,355,000 after acquiring an additional 379,703 shares during the period. Longview Partners Guernsey LTD raised its position in shares of Thermo Fisher Scientific by 6.8% in the fourth quarter. Longview Partners Guernsey LTD now owns 4,876,890 shares of the medical research company’s stock worth $926,024,000 after acquiring an additional 311,977 shares during the period. Elkfork Partners LLC acquired a new position in shares of Thermo Fisher Scientific in the fourth quarter worth about $46,978,000. Finally, Schroder Investment Management Group raised its position in shares of Thermo Fisher Scientific by 28.1% in the fourth quarter. Schroder Investment Management Group now owns 1,103,685 shares of the medical research company’s stock worth $209,568,000 after acquiring an additional 242,062 shares during the period. Institutional investors and hedge funds own 85.86% of the company’s stock.

In related news, Director C Martin Harris sold 206 shares of the company’s stock in a transaction dated Friday, May 18th. The shares were sold at an average price of $214.43, for a total transaction of $44,172.58. Following the completion of the sale, the director now owns 5,106 shares of the company’s stock, valued at approximately $1,094,879.58. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director William G. Parrett sold 1,000 shares of the company’s stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $211.43, for a total transaction of $211,430.00. Following the sale, the director now directly owns 11,660 shares of the company’s stock, valued at approximately $2,465,273.80. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 43,706 shares of company stock valued at $9,173,503. 0.49% of the stock is owned by corporate insiders.

A number of research analysts have weighed in on TMO shares. Zacks Investment Research upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $240.00 price objective for the company in a research report on Thursday, March 22nd. ValuEngine raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Friday, February 2nd. Bank of America boosted their target price on shares of Thermo Fisher Scientific from $235.00 to $250.00 and gave the stock a “buy” rating in a research note on Thursday, February 1st. Leerink Swann reissued an “outperform” rating and set a $239.00 target price (up previously from $200.00) on shares of Thermo Fisher Scientific in a research note on Thursday, February 1st. They noted that the move was a valuation call. Finally, Morgan Stanley boosted their target price on shares of Thermo Fisher Scientific from $216.00 to $230.00 and gave the stock an “overweight” rating in a research note on Thursday, April 26th. One analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $224.38.

TMO stock opened at $216.73 on Tuesday. The stock has a market cap of $86.48 billion, a PE ratio of 22.84, a P/E/G ratio of 1.58 and a beta of 1.14. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.36 and a quick ratio of 0.95. Thermo Fisher Scientific has a 52 week low of $170.07 and a 52 week high of $226.44.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, April 25th. The medical research company reported $2.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.42 by $0.08. Thermo Fisher Scientific had a net margin of 10.24% and a return on equity of 16.09%. The company had revenue of $5.85 billion during the quarter, compared to analysts’ expectations of $5.62 billion. During the same quarter in the prior year, the company earned $2.08 EPS. Thermo Fisher Scientific’s revenue was up 22.8% compared to the same quarter last year. equities analysts anticipate that Thermo Fisher Scientific will post 10.91 EPS for the current fiscal year.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply